Safety study supports clinical development of immunotherapeutic oncolytic measles vaccine

Mol Ther Methods Clin Dev. 2022 Sep 24:27:90-92. doi: 10.1016/j.omtm.2022.09.003. eCollection 2022 Dec 8.

Christine E Engeland^{1

2}

¹ Faculty of Health/School of Medicine, Institute of Virology and Microbiology - Experimental Virology, Center for Biomedical Education and Research (ZBAF), Witten/Herdecke University, Witten, Germany.
² Research Group Mechanisms of Oncolytic Immunotherapy, Clinical Cooperation Unit Virotherapy, German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT) and University Hospital Heidelberg, Department of Medical Oncology, Heidelberg, Germany.

No abstract available

Publication types